|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 574 JPY | +6.30% |
|
+1.95% | -51.02% |
| 05-31 | JCR Pharmaceuticals' Full-Year Profit Up 46% | MT |
| 05-27 | Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold | MT |
JCR Pharmaceuticals Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales to be JPY 45,000 million. Operating income to be JPY 14,500 million.
Earnings per share to be JPY 83.25. Profit attributable to owners of the parent to be JPY 10,300 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -51.02% | 456M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
JCR PHARMACEUTICALS CO., LTD. 
